Table 2.
Baseline characteristics of studies (cont’d)
| Study | Design | Outcomes | No. at risk |
No. of Events |
Mean Age |
Sex (female) |
Follow- up time (yrs) |
Adjusted For | Reason not included | |
|---|---|---|---|---|---|---|---|---|---|---|
| Dem. | AD | |||||||||
| Blasko 2010 | cohort | AD | 406 | -- | 33 | 75.8 | 56.5% | 5 | sex, education, creatinine, smoking, stroke/infarction in MRI, sGDS score, interaction between Aβ42 and APOE | only continuous RR reported |
| Cosentino 2010 | cohort | cognitive change | 880 | -- | -- | 76.1 | 68.0% | 4.5 | age, sex, race, BMI, APOE, recruitment wave | cognitive change as outcome |
| Lopez 2008 | cohort | AD | 274 | -- | 88 | 79.3 | 60.9% | 4.5 (mean) | age | only continuous RR reported |
| Okereke 2009 | cohort | cognitive change | 481 | -- | -- | 63.6 | 100.0% | 10 | age, education, BMI, hypertension, dyslipidemia, heart disease, smoking, HT, physical activity, alcohol, depression | cognitive change as outcome |
| Yaffe 2011 | cohort | cognitive change | 997 | 72 | -- | 74.0 | 55.1% | 10 | age, race, education, diabetes, smoking, APOE | cognitive change as outcome |
Abbreviations: APOE = Apolipoprotein E; BMI = Body Mass Index; HT = postmenopausal hormone therapy; MRI = Magnetic Resonance Imaging; sGDS = short form of the Geriatric Depression Scale
Note: confidence intervals reflect published results, before random-effects weighting